Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million.
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.
The Davis Polk corporate team included partner Alan F. Denenberg and associate Bryan M. Quinn. Partner Patrick E. Sigmon and associate Adam R. Brownstone provided tax advice. Partner David R. Bauer and associate Jennifer Leather provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.